Lifevantage Corp (LFVN) AI Stock Summary

Snapshot

LifeVantage is a profitable small-cap supplement maker with strong margins but recent growth headwinds. In FY 2025, the company generated $228.5M in revenue (up 14.2% YoY) and $9.8M in net income, maintaining a healthy 80.4% gross margin. It produces solid free cash flow of $10.5M and holds $20.2M in cash against $11.7M in debt. However, the most recent quarter showed a sharp 25.2% revenue drop to $43.7M, raising questions about sustainability. The stock trades at a modest P/E of 8.55, well below its 52-week high, reflecting investor caution over the recent slowdown and an incoming CEO change.

What's Happening Right Now

• Wed 6th May '26 · Earnings Miss: Q3 2026 revenue fell 25.2% year-over-year to $43.7M, missing analyst estimates and signaling a slowdown in growth.
• Wed 6th May '26 · Dividend: The company declared a quarterly cash dividend of $0.05 per share, payable in June 2026.
• Tue 21st Apr '26 · Patent: LifeVantage received a U.S. patent for its Healthy Glow Essentials Stack, protecting its cellular signaling supplement formula.
• Thu 16th Apr '26 · Leadership Change: Terrence Moorehead is set to become the new CEO and join the board on August 5, 2026, replacing current leadership.
• Thu 2nd Apr '26 · Expansion: The company announced it will expand its business footprint into Portugal, launching in May 2026.

Ownership

Institutions hold 54.8% of shares, while insiders hold 14.6%.

Bottom Line

LifeVantage is a fundamentally sound business that makes money on every sale and generates real cash. The recent quarterly revenue miss and the upcoming CEO transition are creating uncertainty, which has pushed the stock price down from its highs. At a P/E of 8.55, the market is pricing in significant doubt about future growth. This is not a distressed company, but it is trading at a discount due to near-term execution risks. A reader would need to believe the new leadership can restart growth to find value here.